Search

New York's legal cannabis market has surpassed $2 billion in total sales since its launch in late 2022, with over $1 billion generated in 2025 alone. The Office of Cannabis Management (OCM) and Cannabis Control Board (CCB) are approving more licenses, with a focus on social equity, and extending deadlines for provisional licenses due to zoning issues. The state is also launching a Cannabis Education Advisory Panel, extending tax return deadlines for businesses, and providing grants to justice-involved retail marijuana businesses. Enforcement against the illicit market continues to be a priority, and there are plans to expand licensing rules to potentially allow cannabis sales in movie theaters. < Back New York Stores Have Sold $1 Billion In Legal Marijuana This Year So Far, With Market Topping $2 Billion Since Launch Sep 9, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link New York officials are touting a marijuana milestone, with the state exceeding $2 billion in cannabis sales since the market launched. And $1 billion of those purchases have been made in 2025 alone. At a meeting on Tuesday, the Office of Cannabis Management (OCM) announced that the state has reached $2.09 billion in total adult-use marijuana sales since the first retailers opened in late 2022. After initial setbacks in the market rollout, the industry has greatly expanded, with $1.06 billion in cannabis purchases this year. As part of the marijuana sector’s maturation, the Cannabis Control Board (CCB) separately announced that it is approving 46 additional adult-use cannabis business licenses, raising the total to 1,904. And regulators said 57 percent of those businesses are owned by social equity licensees. “Our work extends far beyond issuing licenses and setting regulations, it’s about shaping a cannabis industry that truly reflects the values of New York,” Jessica García, chair of CCB, said. “Every decision we make is rooted in equity, transparency, and a long-term vision for a thriving market.” 💰 MARKET UPDATE: New York’s legal cannabis market has surpassed $2 billion in total retail sales, with $1.06 billion generated just this year. Sales per store have climbed for the second month in a row, signaling strong demand and growing stability in #NYcannabis. — NYS Office of Cannabis Management (@nys_cannabis) September 9, 2025 “Together with OCM, we are building a system that communities can trust, one that creates opportunity, protects public health, and ensures this industry serves every corner of our state for generations to come,” she said. Simone Washington, chief equity officer at OCM, said that as the state aims “to maintain our commitment to ensuring equity in the licensing process, OCM is equally attuned to ensuring that [social equity] licensees have the necessary resources and supportive services to enable longevity in the market.” “Their long-term sustainability is a marker of our collective success,” she said. “The current slate of SEE programs is designed to meet the needs of SEE licensees at every stage of the business development cycle.” Meanwhile, given confusion within the marketplace about timelines for provisional licenses, CCB said it will be extending the renewal deadline for conditional adult-use until December 31, 2026. “This extension provides licensees additional time to secure viable locations and move toward full licensure,” OCM said. “It will also apply to any provisional licenses issued between September 9, 2025, and December 30, 2025, ensuring clarity and consistency for all provisional license holders.” Part of the uncertainty surrounding provisional licensees concerns a recently identified zoning issue impacting more than 100 cannabis businesses that are apparently located too close to public schools or places of worship than is allowed under current statute. Gov. Kathy Hochul (D) has said that she will be pushing the legislature to amend the state’s marijuana law to address the issue. CCB on Tuesday also approved the creation of a Cannabis Education Advisory Panel (CEAP), which will focus on public outreach to promote youth education around marijuana. “The launch of the Cannabis Education Advisory Panel is an exciting step forward in OCM’s work to ensure that the needs of communities and the perspectives of folks who are deeply engaged in public health show up in the work of the agency,” Felicia A.B. Reid, acting executive director of OCM, said. “Information is power and education is the heartbeat of progress. Through CEAP, OCM looks to empower communities to make informed choices and foster a deeper sense of trust in New York’s evolving cannabis industry.” *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* Meanwhile, both chambers of the New York legislature recently passed legislation that would extend the deadline for some marijuana businesses to file electronic tax returns, sending the proposal next to the governor’s desk. If signed into law, the measure would give cannabis manufacturers and distributors 30 extra days to submit their tax returns following the end of each quarterly tax period. Currently the companies have a 20-day window to file the documents, which the legislation would extended to 50 days. Sponsors of the bill have noted that Hochul vetoed an earlier cannabis business tax reform proposal late last year, claiming it would “pose significant operational challenges for the State and confusion for taxpayers,” but that they’ve worked to address those concerns in the current version. The earlier, vetoed measure would have allowed marijuana growers and processors to pay excise taxes on an annual basis rather than quarterly—a change that would have extended the same treatment to cannabis as the state already offers the alcohol industry. In July, meanwhile, New York officials announced the first round of grants under a $5 million program to help retail marijuana businesses owned by justice-involved people cover startup costs. About three months after opening up applications for the Conditional Adult-Use Retail Dispensary (CAURD) Grant Program, OCM and Empire State Development (ESD) announced on Wednesday that they have awarded 52 licensed dispensaries up to $30,000 each in funds meant for startup and operational costs such as rent, renovations, inventory tracking and security systems. To qualify for the program, applicants need to have been “justice involved”—in other words, impacted by a marijuana-related conviction—and have some experience running a profitable business. Meanwhile, OCM recently launched a new online map that’s meant to help adults locate licensed marijuana retailers—one of their latest efforts to encourage consumers to buy their cannabis from the regulated market. After a rocky rollout of the state’s legalization law opened the door to a proliferation of illicit marijuana shops, the governor and regulators have prioritized educating the public about the need to purchase their products from licensed dispensaries as a health and safety imperative. The broader New York campaign has also involved digital ads and educational resources, including a guide on safe consumption practices, as well as graphics and videos featuring licensed cannabis business owners and messaging about the benefits of participating in the regulated market. OCM also advises that “continued enforcement against the illicit market is critical to building a health regulated market,” pointing to what it describes as successful enforcement efforts in 2024. Last spring, for example, officials in New York City launched Operation Padlock, an enforcement initiative meant to shutter illegal storefronts. Within months, licensed shops that were open before the operation began saw sales climb 105 percent, according to an OCM survey. Regulators are also moving forward with new proposed regulations around the state’s so-called “cannabis showcase” program, which allows licensed businesses to sell to consumers at pop-up, farmers market-like events. As originally authorized, the showcase events were largely in response to the slow rollout of New York’s adult-use marijuana program, which faced multiple delays in implementation amid litigation and other matters. Separately Hochul signed state budget legislation that did not include a controversial earlier provision that would have allowed police to use the smell of marijuana as probable cause that a driver is impaired and then force them to take a drug test. Amendments made in the legislature removed the provision, which a coalition of 60 reform groups had argued in a letter to Hochul and top lawmakers would “repeat some of the worst harms of the War on Drugs” and allow law enforcement to “restart unconstitutional racial profiling of drivers.” In April, New York cannabis regulators and labor officials announced the launch of a workforce training program aimed at “providing comprehensive safety education to workers” in the state’s legal marijuana industry. Separately, OCM’s press secretary indicated the office is working on plans to expand permitting and licensing rules that could allow adults to buy and consume marijuana at movie theaters. Authorizing sales of cannabis products at theaters would set New York apart as it continues to build upon the state’s legalization law. Earlier this year, a collective of businesses licensed under the CAURD program called on Hochul to forgive tens of millions of dollars in high-cost loans issued under a governor-created social equity loan fund. A state lawmaker said in December that there’s a need to extend financial aid to CAURD license holders, many of whom are struggling under the high-cost loans. Critics—including the NAACP New York State Conference, Black Cannabis Industry Association, Minority Cannabis Business Association, Service Disabled Veterans in Cannabis Association, Drug Policy Alliance, NYC NORML and VOCAL-NY—wrote to the governor earlier that month to express dismay at what they described as marijuana regulators’ “efforts in service of big corporations at the expense of small business and equity outcomes.” The post New York Stores Have Sold $1 Billion In Legal Marijuana This Year So Far, With Market Topping $2 Billion Since Launch appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

US House Passes Bill Protecting State Medical Marijuana Laws And Rejecting Attempt To Block Trump’s Rescheduling Move < Back US House Passes Bill Protecting State Medical Marijuana Laws... Jan 8, 2026 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The U.S. House of Representatives has approved a spending bill that would continue protecting state medical marijuana programs from federal intervention—while excluding a provision that previously advanced to block the Justice Department from rescheduling cannabis. Following bicameral negotiations on the appropriations package, the House advanced it in a 397-28 vote on Thursday, sending it to the Senate for consideration. Advocates and industry stakeholders were encouraged to see the rescheduling language stripped from the final deal after it had been approved by the House Appropriations Committee last year, as well as the preservation of a longstanding rider preventing DOJ from using its funds to interfere in state medical marijuana laws. The legislation that’s now advancing to the Senate covers Fiscal Year 2026 spending for Commerce, Justice, Science, and Related Agencies (CJS), Interior, Environment and Energy and Water Development. The move comes weeks after President Donald Trump issued an executive order directing Attorney General Pam Bondi to expeditiously complete the process of moving marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). *Here’s the language of the provision advanced by the House but excluded from the latest agreement: * “SEC. 607. None of the funds appropriated or other wise made available by this Act may be used to reschedule marijuana (as such term is defined in section 102 of the Controlled Substances Act (21 U.S.C. 802)) or to remove marijuana from the schedules established under section 202 of the Controlled Substances Act (21 U.S.C. 812).” GOP senators have separately tried to block the administration from rescheduling cannabis as part of a standalone bill filed in 2023, but that proposal did not receive a hearing or vote. Meanwhile, on Monday, the Drug Enforcement Administration (DEA) said a marijuana rescheduling appeal process “remains pending” despite Trump’s executive order. The House-passed appropriations package also contains a rider that’s been annually renewed since 2014 barring the Justice Department from using its funds to interfere in the implementation of state medical marijuana laws. However, for reasons that are unclear, the rider that lists each state that would be protected excludes Nebraska. *Here’s the text of that provision: * “SEC. 531. None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, the Commonwealth of the Northern Mariana Islands, the United States Virgin Islands, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.” Missing from the latest version is an addition to that rider that the House previously included that would have authorized enhanced penalties for sales near schools and parks. That provision specifically stipulated that the Justice Department could still enforce a section of U.S. code that calls for increased penalties for distributing cannabis within 1,000 feet of an elementary school, vocational school, college, playground or public housing unit. However, a joint explanatory statement for the spending package also says Congress “directs the Department to appropriately enforce the Federal Drug-Free School Zones Act (2 1 U.S.C. 860), to ensure that areas with young children, including schools and playgrounds remain drug-free.” That appears to be related to a report from the Senate committee that was released last year stating that the medical marijuana protection rider “does not explicitly preclude” U.S. attorneys from enforcing a federal statute on selling or manufacturing controlled substances in “areas with young children, including schools and playgrounds.” *The bill also maintains protections for state industrial hemp research programs under the 2014 Farm Bill: * “SEC. 530. None of the funds made available by this Act may be used in contravention of section 7606 (‘Legitimacy of Industrial Hemp Research’) of the Agricultural Act of 2014 (Public Law 113–79) by the Department of Justice or the Drug Enforcement Administration.” Advocates may welcome the exclusion of the rescheduling provision and inclusion of medical marijuana protections in the CJS bill, but many cannabis stakeholders have protested Trump’s signing of a separate appropriations measure in November that includes provisions to ban most consumable hemp products. However, when the president issued the marijuana rescheduling order last month, he also directed Congress to reevaluate that policy and ensure that people can continue to access full-spectrum CBD products. A federal agency will also be moving to cover such products for certain patients under Medicare and Medicaid. The post US House Passes Bill Protecting State Medical Marijuana Laws And Rejecting Attempt To Block Trump’s Rescheduling Move appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The Cannabis industry stands at a pivotal crossroads in 2025. With federal rescheduling proceedings facing unexpected delays and a new administration settling into office, Cannabis businesses and their accountants face significant uncertainty about the regulatory landscape ahead. Understanding these complex policy developments is essential for Cannabis businesses to navigate compliance requirements and prepare for potential changes that could dramatically impact their operations and tax obligations. In this comprehensive analysis, we explore the current state of Cannabis rescheduling efforts, examine the political dynamics at play in Washington, and provide strategic guidance for Cannabis businesses and their financial advisors during this transitional period. The Long Road to Rescheduling: How We Got Here Since the passage of the Controlled Substances Act in 1970, Cannabis has been classified as a Schedule I substance—a category reserved for drugs with "no accepted medical use" and "high potential for abuse." This classification has placed Cannabis in the same category as heroin and LSD, despite mounting scientific evidence of its medicinal benefits and moderate risk profile. < Back Cannabis Rescheduling in 2025: Expert Insights on Federal Policy Changes Feb 3, 2025 Dope CFO Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The Cannabis industry stands at a pivotal crossroads in 2025. With federal rescheduling proceedings facing unexpected delays and a new administration settling into office, Cannabis businesses and their accountants face significant uncertainty about the regulatory landscape ahead. Understanding these complex policy developments is essential for Cannabis businesses to navigate compliance requirements and prepare for potential changes that could dramatically impact their operations and tax obligations. In this comprehensive analysis, we explore the current state of Cannabis rescheduling efforts, examine the political dynamics at play in Washington, and provide strategic guidance for Cannabis businesses and their financial advisors during this transitional period. The Long Road to Rescheduling: How We Got Here Since the passage of the Controlled Substances Act in 1970, Cannabis has been classified as a Schedule I substance—a category reserved for drugs with "no accepted medical use" and "high potential for abuse." This classification has placed Cannabis in the same category as heroin and LSD, despite mounting scientific evidence of its medicinal benefits and moderate risk profile. The Biden administration initiated a scientific review of Cannabis scheduling in 2022, directing the Department of Health and Human Services (HHS) to evaluate whether Cannabis belonged in Schedule I. After conducting a comprehensive analysis, HHS recommended in 2023 that Cannabis be reclassified as a Schedule III substance, acknowledging its legitimate medical applications and relatively lower abuse potential compared to Schedule I and II substances. This recommendation represented a monumental shift in federal policy. Schedule III substances, which include medications like Tylenol with codeine and ketamine, are recognized as having medical value while still maintaining certain controls. For Cannabis businesses, this reclassification would deliver significant benefits—most notably the elimination of the punitive Section 280E tax provision that currently prevents Cannabis businesses from deducting ordinary business expenses. "This isn't just about rescheduling—it's about undoing decades of prohibition policy and replacing it with sensible regulations that allow a flourishing industry," explains Aaron Smith, co-founder and CEO of the National Cannabis Industry Association (NCIA). "While full federal legalization remains the ultimate goal, rescheduling to Schedule III would represent the most significant federal Cannabis reform since prohibition began." The December 2nd Hearing and Unexpected Complications The Drug Enforcement Administration (DEA) initiated formal proceedings to consider HHS's recommendation, scheduling administrative hearings that began on December 2, 2024. These hearings were to be presided over by an administrative law judge who would make a non-binding recommendation to the DEA administrator on whether to proceed with rescheduling. In an unprecedented development, the DEA—which historically has resisted Cannabis reform—positioned itself as the proponent of rescheduling during these proceedings, with opponents having the burden to demonstrate why Cannabis should remain in Schedule I. However, what should have been a straightforward process took a complex turn when certain pro-annabis entities, including Village Farms and veterans' advocacy groups, filed motions to stay the proceedings. These organizations alleged improper communications between the DEA and prohibitionist groups like Smart Approaches to Marijuana (SAM), and questioned whether the DEA was genuinely committed to rescheduling despite its stated position. "These hearings have been indefinitely postponed following the stay," Smith notes. "From our perspective, this was an unfortunate and misguided strategy. The judge was clearly indicating that these proceedings could move forward efficiently, but now we're looking at significant delays that could extend for months." The stay raises serious questions about the timeline for rescheduling, especially with the transition to a new administration. While the previous attorney general had personally signed the proposed rule to reschedule Cannabis—an unusual step indicating high-level political support—the appointment of new leadership at the Department of Justice and DEA creates additional uncertainty. The Trump Administration's Approach to Cannabis Policy With Donald Trump's return to the White House and his nomination of key cabinet officials, Cannabis industry stakeholders are closely analyzing potential policy directions. During his campaign, Trump expressed support for state-level Cannabis legalization efforts and hinted at potential federal reform. The critical appointments to watch include: 1. *RFK Jr. as Secretary of Health and Human Services* – Kennedy has historically supported Cannabis reform but has indicated he would defer to the DEA on rescheduling decisions, despite HHS having conducted the scientific evaluation that recommended rescheduling. 2. *Pam Bondi as Attorney General* – As Florida's former attorney general, Bondi opposed a state constitutional amendment to expand medical Cannabis access, calling the measure's wording "misleading." Her position on federal Cannabis policy remains unclear. 3. *DEA Administrator* – This pending appointment will be crucial, as the DEA retains significant authority over the rescheduling process and could potentially delay or accelerate the administrative proceedings. "While Cannabis may not be a top priority for the new administration, there are reasons for cautious optimism," Smith observes. "President Trump understands this is a multi-billion dollar industry with strong public support, particularly among demographics that were important to his electoral coalition. There's political advantage in moving forward with reform." The administration's approach to Cannabis could mirror its handling of other policy areas, with the president delegating authority to cabinet secretaries to develop and implement policies in their respective domains. For Cannabis, this likely means RFK Jr. at HHS will have significant influence over the federal government's approach to medical Cannabis. Potential Pathways Forward for Federal Cannabis Reform Several potential pathways exist for Cannabis policy reform in 2025: 1. Administrative Rescheduling The most immediate pathway remains the DEA's administrative process. Once the stay on proceedings is resolved, hearings could resume, leading to a recommendation from the administrative law judge and ultimately a decision by the DEA administrator. "The president has the authority to direct the DEA to reschedule Cannabis," Smith explains. "While this would require navigating institutional resistance within the agency, clear direction from the White House could accelerate the process significantly." 2. Congressional Action With Republicans controlling both chambers of Congress, Cannabis legislation faces a challenging environment. However, bipartisan support exists for certain reforms, particularly around banking access. "Look for Cannabis provisions to be attached to larger legislative vehicles rather than standalone bills," Smith advises. "The Senate Banking Committee has already held hearings on 'debanking' where Cannabis banking issues were raised. These entry points provide opportunities to advance incremental reforms." 3. Executive Action While less likely, the president has the authority to direct sweeping changes through executive action. "The administration could theoretically direct the DEA to remove Cannabis from the Controlled Substances Act altogether," Smith notes. "While this would create a regulatory vacuum that might necessitate congressional action, it would immediately end federal prohibition." 4. State-Level Momentum Regardless of federal developments, state-level legalization continues to expand. Ohio and Minnesota are implementing adult-use Cannabis markets in 2025, joining the growing number of states with regulated Cannabis programs. This expanding state-level framework continues to increase pressure for federal reform. Financial Implications for Cannabis Businesses For Cannabis businesses and their financial advisors, the potential rescheduling presents significant implications: 1. Section 280E Relief The most immediate benefit of rescheduling would be relief from Section 280E of the Internal Revenue Code, which prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. This provision creates effective tax rates of 60-70% for many Cannabis operations. "Rescheduling to Schedule III would allow Cannabis businesses to deduct normal business expenses like any other industry," explains Andrew Hunzicker, CPA and Cannabis accounting specialist. "This would dramatically improve cash flow and profitability across the sector." 2. Banking and Financial Services While rescheduling alone wouldn't completely resolve banking challenges, it would reduce the risk profile for financial institutions serving Cannabis businesses, potentially expanding access to banking services, loans, and merchant processing. 3. Capital Markets and Investment The regulatory certainty provided by rescheduling would likely attract significant new investment into the Cannabis sector. Public Cannabis companies would benefit from reduced compliance costs and improved profitability, potentially driving valuations higher. 4. Compliance Requirements Even with rescheduling, Cannabis would remain a controlled substance with specific regulatory requirements. Businesses would need to adapt their compliance programs to any new federal frameworks that emerge alongside rescheduling. Strategic Recommendations for Cannabis Businesses in 2025 Given the uncertain policy environment, Cannabis businesses and their accountants should consider the following strategic approaches: 1. Prepare for Multiple Scenarios Develop contingency plans for different potential outcomes, including: - Successful rescheduling to Schedule III - Extended delays in the administrative process - Congressional action on specific issues like banking - Continued status quo with state-level regulation and federal prohibition 2. Maintain Robust Compliance Systems Regardless of rescheduling outcomes, maintaining detailed financial records and strict regulatory compliance remains essential. Businesses should document their operations meticulously, particularly in areas that may be scrutinized under 280E such as cost of goods sold calculations. 3. Engage in Advocacy Efforts Industry participation in advocacy efforts can influence policy outcomes. "This is a movement as much as an industry," Smith emphasizes. "Businesses that engage with organizations like NCIA can help shape the policies that will govern the future of legal Cannabis." 4. Optimize Current Tax Strategies While awaiting potential 280E relief, businesses should work with Cannabis-specialized accountants to implement appropriate cost accounting methodologies that maximize deductible expenses within the current regulatory framework. 5. Monitor Political Developments Closely The rapidly evolving political landscape requires constant monitoring. Key indicators to watch include: - Appointments to relevant agencies like the DEA - Statements from administration officials on Cannabis policy - Congressional hearings related to banking or controlled substances - Court decisions that may impact administrative proceedings Conclusion: Navigating Uncertainty While Preparing for Change The Cannabis industry has repeatedly demonstrated resilience through regulatory uncertainty and political shifts. While the path to federal reform remains complex, the direction of travel continues toward expanded recognition of Cannabis's legitimate medical applications and economic contributions. "Despite the current procedural delays, we're closer than ever to meaningful federal reform," Smith concludes. "The scientific evidence supporting rescheduling is overwhelming, public support continues to grow, and the economic case for reform becomes stronger with each new state market that comes online." For Cannabis businesses and their financial advisors, the coming months and years require vigilance, adaptability, and strategic foresight. By understanding the complex political and regulatory dynamics at play, businesses can position themselves to thrive regardless of how federal policy evolves in 2025 and beyond. [Click here to listen to our conversation with NCIA CEO Aaron Smith.] < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The cannabis industry's "adolescence" ended in 2025, forced by price compression and oversupply to shift from rapid growth and improvisation to disciplined, efficient operations and professional management. This maturation led to a focus on consistent quality, technology adoption, and stability as new competitive advantages, resulting in more reliable products and greater transparency for consumers. < Back Cannabis Grows Up: Why 2025 Marked the Industry’s Turning Point Dec 30, 2025 Chris Mapson MG Magazine Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link For much of its existence, the legal cannabis industry operated like a precocious teenager: full of promise, ambition, and energy, but often fueled by improvisation and optimism more than discipline. Growth felt inevitable. Capital flowed freely. Expansion was celebrated, sometimes without regard for sustainability. But in 2025, that adolescence ended. The past year brought a sobering mix of price compression, persistent oversupply, tightening capital markets, and continued regulatory uncertainty. For many operators, the situation was painful. For some, existential. Yet these pressures may prove to be the most important catalysts the industry has faced to date. Because in being forced to confront reality, cannabis began its transition from youthful exuberance to adulthood. 2025 was the cannabis industry’s reality check The headwinds of 2025 exposed structural weaknesses that long had been masked by rapid growth and investor enthusiasm. Unsustainable expansion models, bloated cost structures, and vague paths to profitability no longer could be ignored. The era of growth at all costs ended abruptly as operators faced a hard truth: Scale without efficiency is a liability, not an asset. Increasing competition compounded these challenges. As more brands fought for shelf space and consumer attention, inefficiencies became impossible to hide. Many businesses were forced to make difficult decisions like exiting markets, streamlining operations, cutting SKUs or rethinking entire strategies. While painful, these moments of reckoning were necessary. 2025 became the year cannabis businesses were forced to grow up. Discipline replaces experimentation One of the clearest signs of maturation has been the shift away from improvisation and intuition and toward process-driven decision-making. In earlier years, companies relied on gut instinct, trial-and-error approaches, and rapid experimentation. Today, discipline is replacing spontaneity. Operators are paying closer attention to fundamentals by controlling costs, managing margins, and building product portfolios with clear strategic intent. Inventory and supply-chain planning have become more deliberate, reducing waste and excess. Marketing, too, has matured. Data-driven campaigns, sharper brand positioning, and fewer “me too” products are becoming the norm as companies seek to stand out through clarity rather than noise. Technology as a marker of maturity Technology adoption has emerged as one of the strongest indicators of the industry’s coming of age. Across cultivation, manufacturing, retail, and post-harvest operations, businesses increasingly are turning to technology to reduce variability and improve consistency. In cultivation, advanced environmental controls and optimization tools are helping growers fine-tune conditions, improve yields, and reduce risk. Science-backed and proven post-harvest technologies and standard operating procedures are replacing legacy processes that heavily relied on experience and guesswork, enabling more consistent quality and better product preservation. At the retail level, analytics platforms are delivering deeper consumer insights, improved demand forecasting, and more efficient inventory management. Collectively, these tools are doing more than merely improving operations. They are changing the industry’s mindset. Technology is replacing guesswork with repeatability, enabling cannabis businesses to operate with the predictability expected of mature industries. Quality, not volume, defines the next era Oversupply has forced a long-overdue reassessment of what actually sells. Simply producing more of whatever you produce is no longer a viable strategy. Instead, consistent quality, reliable experiences, and transparent processes are becoming the true differentiators. Consumers are increasingly discerning, and they expect products that deliver on their promises every time. Brands that prioritize quality over volume and can demonstrate consistency across batches and formats are better positioned to earn loyalty. In this next era, better — not more — products will determine long-term winners. Professional leadership reshapes cannabis businesses Another hallmark of maturity is the influx of seasoned executives and operators from adjacent industries such as food and beverage, agriculture, consumer packaged goods, and technology. Their presence has brought stronger governance, clearer key performance indicators, and greater operational accountability. This shift is also cultural. Cannabis increasingly is being treated as a real business that still values passion and mission but no longer relies on them alone. Professional management, disciplined execution, and long-term planning are becoming expectations rather than exceptions. While much of this evolution has occurred behind the scenes, consumers stand to gain the most. A more disciplined industry delivers better product consistency, stronger safety and testing standards, and more thoughtful innovation. As companies refine processes and adopt proven systems, consumers can expect products that are more reliable from manufacturers and cultivators who are more transparent about their processes. Why stability is now a competitive advantage As cannabis moves beyond adolescence, stability itself is becoming a competitive advantage. Companies that survived 2025 are leaner, more focused, and better prepared for what comes next, whether that includes recently announced federal reforms, expanded markets or new consumer segments. Success is being redefined around resilience, adaptability, and sustainability rather than hype and rapid expansion. The cannabis industry’s carefree adolescence is fading, and with it, some of the myths that once defined the space. The growing pains are far from over, but the industry is stronger because of them. Through challenge and turmoil, cannabis has begun to evolve into a more disciplined, credible, and enduring business. The cannabis industry is no longer chasing legitimacy. It’s earning it. ------------------------------ FAQ: How 2025 Changed the Cannabis Industry 1. Why was 2025 a turning point for the cannabis industry? 2025 exposed long-standing structural weaknesses in cannabis, including unsustainable growth models, bloated costs, and vague paths to profitability, forcing operators to mature quickly. 2. How did price compression affect cannabis operators? Price compression reduced margins across cultivation, manufacturing, and retail, making efficiency, cost control, and disciplined operations essential for survival. 3. What role did technology play in cannabis industry maturation? Technology helped replace guesswork with repeatability, enabling better environmental control, inventory management, and data-driven decision-making across the supply chain. 4. Why is quality more important than volume in cannabis now? Oversupply revealed that consistent quality and reliable consumer experiences—not sheer output — are the true drivers of brand loyalty and long-term success. 5. What does cannabis industry maturity mean for consumers? A more mature cannabis industry delivers better consistency, stronger safety standards, and greater transparency, resulting in more reliable products and experiences. ------------------------------ [image: Chris Mapson Cannatrol] An accomplished marketing leader with more than twenty-five years of experience, Chris Mapson is executive vice president of marketing for *Cannatrol*, a leader in precision cannabis drying, curing, and storage technology. Previously, he served as vice president of marketing at LivWell Enlightened Health/Pharmacann and marketing and creative director at The Green Solution. Additionally, he has held roles at CenturyLink, Sony, and Aramark. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

D.C. medical cannabis sales surged to $5.46 million in April 2025, generating a 90% increase in tax revenue compared to the previous year, yet cannabis remains one of the city's lowest-taxed goods at 6%. < Back D.C. cannabis tax revenue soars but unlikely to trickle down to equity fund Jun 2, 2025 Editorial Staff Outlaw Report Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link D.C. medical cannabis sales surged to $5.46 million in April 2025, generating a 90% increase in tax revenue compared to the previous year, yet cannabis remains one of the city's lowest-taxed goods at 6%. Source < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

From California to New York, small farms are diversifying by offering craft marijuana and produce at farmers markets and through community-supported agriculture programs. Farmers markets want to sell marijuana, but there are restrictions. < Back Farmers markets want to sell marijuana; here’s why they can’t May 22, 2025 Chris Roberts MJ Biz Daily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link From California to New York, small farms are attempting to diversify by offering craft marijuana along with produce at farmers markets and via community-supported agriculture programs. Farmers markets want to sell marijuana; here’s why they can’t is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Texas Governor Greg Abbott wants lawmakers to regulate hemp THC products like alcohol after vetoing a bill to ban most consumable cannabinoids. He proposed a regulatory framework with age restrictions, zoning requirements, and bans on public consumption. A special legislative session will address this issue, with hemp advocates and veterans opposing the ban. < Back Texas Governor Tells Lawmakers To Regulate Hemp THC Products Like Alcohol After Vetoing Bill To Ban Most Consumable Cannabinoids Jun 23, 2025 Staff Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The governor of Texas says that, rather than outright ban consumable hemp products, lawmakers should establish a regulatory framework that treats cannabinoids “similar to the way alcohol is regulated.” After vetoing a controversial bill on Sunday that would have effectively eliminated the state’s hemp market, Gov. Greg Abbott (R) proposed an extensive list of policy changes that he says he would support—and which the legislature will have the chance to enact during a special session the governor is convening next month. “Texans on each side of the Senate Bill 3 debate raise serious concerns. But one thing is clear—to ensure the highest level of safety for minors, as well as for adults, who obtain a product more dangerous than what they expected, Texas must strongly regulate hemp, and it must do so *immediately,*” Abbott said. Part of the rationale behind his veto was the risk of litigation over “valid constitutional challenges” that he suggested would hold up in court. And to that end, multiple top Texas hemp companies did file a preemptive lawsuit challenging the legislation, SB 3, before the governor’s veto. “If I were to allow Senate Bill 3 to become law, its enforcement would be enjoined for years, leaving existing abuses unaddressed,” Abbott said in his veto message. “Texas cannot afford to wait.” “At worst, Senate Bill 3 would be permanently invalidated by the courts; at best, its implementation would be delayed for years as the case winds its way through the legal system,” he said. “We can do better.” Rather than face the possibility of having the law enjoined, or indefinitely delayed, the governor said the state “must enact a regulatory framework that protects public safety, aligns with federal law, has a fully funded enforcement structure, and can take effect without delay.” “Legislators could consider a structure similar to the way alcohol is regulated, with strict enforcement by an agency like the Texas Alcoholic Beverage Commission,” he said, adding a list of recommended policies he wants to see lawmakers adopt that include age restrictions, zoning requirements and bans on public consumption. *Here’s the full list of the governor’s recommended hemp regulations:* - Selling or providing a THC product to a minor must be punishable as a crime. - Sales must be prohibited near schools, churches, parks, playgrounds, and other areas frequented by children. - Packaging must be child-resistant, tamper-evident, and resealable; - Products must not be made, packaged, or marketed in a manner attractive to children. - Any store selling these products must have a permit and restrict access to anyone under the age of 21, with strict penalties for any retailer that fails to comply. - Products containing THC may not contain other psychoactive substances (e.g., alcohol, tobacco, kratom). - Testing must be required at every phase of production and manufacturing, including for both plants and derivative consumable products. - Manufacturing and processing facilities must be subject to permitting and food safety rules. - Permit and registration fees must suffice to support robust enforcement and testing by the Texas Alcoholic Beverage Commission, in partnership with other state agencies. - An operator’s permit and warning/danger signs must be posted at any store selling these products. - Sales must be limited to the hours between 10:00 a.m. and 9:00 p.m., and prohibited on Sundays. - The amount of THC permissible in each product must be restricted and an individual may make only a limited number of purchases in a given period of time. - Labels must include a surgeon general-style warning, a clear disclosure of all ingredients, including the THC content, and a scannable barcode or QR code linking to test results. - Fraudulently creating or displaying manifests or lab results must be punishable as felony offenses. - Public consumption, consumption on the premises of any store that sells these products, and possession of an open container in a vehicle must be punishable as crimes. - The Attorney General, district attorneys, and county attorneys must have authority to pursue violations under the Deceptive Trade Practices Act. - Local governments must have the option to prohibit or limit stores selling these products. - Excise taxes must be assessed on these products to fund oversight and enforcement. - Additional funding must be provided to ensure law enforcement have sufficient resources to vigorously enforce restrictions. “This list, of course, is not exhaustive. But it may provide items to consider in a regulatory system that is strict, fair, and legally sustainable,” Abbott said. “Passing a law is not the same thing as actually solving a problem. Texas needs a bill that is enforceable and will make our communities safer today, rather than years from now. Next month, the Legislature will have the opportunity to address this serious issue. I look forward to working with them to ensure that we get it right.” Abbott on Sunday called a special session of a legislature to begin on July 21, saying in a press release that SB 3 and other vetoed bills would be placed on the agenda for further consideration. Hemp advocates and stakeholders had delivered more than 100,000 petition signatures asking Abbott to veto the measure. Critics of the bill argued that the industry—which employs an estimated 53,000 people—would be decimated if the measure became law. Texas lawmakers legalized the sale of consumable hemp in 2019, following enactment of the 2018 federal Farm Bill, which legalized the plant nationwide. That’s led to an explosion of products—including edibles, drinks, vape products and cured flower—sold by an estimated 8,000 retailers. Military veterans advocates, including Texas Veterans of Foreign Wars, have also called on the governor to veto the hemp ban, saying it “would cause irreversible harm to communities across the state.” Farmers have also said the prohibition would devastate a key sector of the state’s agriculture industry. Lt. Gov. Dan Patrick (R), who championed the hemp ban legislation this session, criticized Abbott’s move to veto the bill. “His late-night veto, on an issue supported by 105 of 108 Republicans in the legislature, strongly backed by law enforcement, many in the medical and education communities, and the families who have seen their loved ones’ lives destroyed by these very dangerous drugs, leaves them feeling abandoned,” he said on social media. “I feel especially bad for those who testified and poured their hearts out on their tragic losses.” Meanwhile, a recent survey from a GOP pollster affiliated with President Donald Trump showed that Texas Democratic and Republican voters are unified in their opposition to the hemp ban bill. Another poll commissioned the Texas Hemp Business Council (THBC) found that Texas Republican primary voters oppose the proposal. On Saturday, the governor signed bill to significantly expand the state’s medical marijuana program with new qualifying conditions additional product forms and more dispensary locations. *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* Abbott separately signed a bill into law this month to create a state-backed research consortium to conduct clinical trials on ibogaine as a possible treatment for substance use disorders and other mental health conditions. The ultimate goal of the project is to develop the psychedelic into a prescription drug with federal Food and Drug Administration (FDA) approval, with the state retaining a portion of the profit. The measure expands the state’s list of medical cannabis qualifying conditions to include chronic pain, traumatic brain injury (TBI), Crohn’s disease and other inflammatory bowel diseases, while also allowing end-of-life patients in palliative or hospice care to use marijuana. Separately in Texas, a House committee approved a Senate-passed bill last month that would prohibit cities from putting any citizen initiative on local ballots that would decriminalize marijuana or other controlled substances—as several localities have already done despite lawsuits from the state attorney general. Under the proposal, state law would be amended to say that local entities “may not place an item on a ballot, including a municipal charter or charter amendment, that would provide that the local entity will not fully enforce” state drug laws. While several courts have previously upheld local cannabis decriminalization laws, an appellate court comprised of three conservative justices appointed by the governor has recently pushed back against two of those rulings, siding with the state in its legal challenge to the marijuana policy in Austin and San Marcos. Despite the ongoing litigation and advancement of the House and Senate bills, Texas activists have their targets set on yet another city, Kyle, where they hope put an initiative before voters to enact local marijuana reform at the ballot this coming November. A recent poll found that four in five Texas voters want to see marijuana legalized in some form, and most also want to see regulations around cannabis relaxed. *Read the governor’s veto message on the hemp bill below: * Alabama Cannabis Regulators Grant Medical Marijuana Testing License To Foley-Based Lab The post Texas Governor Tells Lawmakers To Regulate Hemp THC Products Like Alcohol After Vetoing Bill To Ban Most Consumable Cannabinoids appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Jeff Wu, founder of Xylem Robotics, discusses the critical need for cannabis manufacturers to adopt Good Manufacturing Practices (GMP) and ISO standards to survive and thrive in an increasingly regulated market. He explains that cannabis manufacturing is a hybrid of consumer packaged goods (CPG) and pharmaceuticals, emphasizing the importance of a well-run supply chain with product consistency and quality. Wu advocates for flow manufacturing over batch systems, highlighting its efficiency, scalability, and ability to ensure consistency and quality, which are crucial for customer satisfaction and retention. He also stresses that compliance is a financial safeguard, preventing costly recalls and legal exposure. Wu advises operators to begin with documentation and creating standard operating procedures (SOPs) as a first step towards GMP and ISO compliance, which he believes will be mandated with federal legalization. < Back Jeff Wu on Manufacturing, Compliance, and Culture Oct 8, 2025 Taylor Engle MG Magazine Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link [image: Jeff Wu] Cover Story JEFF WU ON COMPLIANCE, CULTURE, AND CANNABIS MANUFACTURING’S FUTURE The Xylem Robotics founder explains why GMP and ISO standards are no longer optional for operators who want to survive — and thrive. By TAYLOR ENGLE Photos by Andrew Strother ------------------------------ The cannabis industry is no stranger to turbulence. Operators across the country face complex challenges: record consumer demand, heightened regulatory uncertainty, and a marketplace that rewards speed as vigorously as it punishes mistakes. In this environment, decisions made today can have unforeseen long-term consequences. Operators who underestimate the operational complexity of manufacturing risk setbacks that can ripple across their entire business. Each choice, from equipment selection to employee training, carries weight far beyond the immediate outcome. Across the spectrum, from cultivation to manufacturing and retail, the stakes are higher than ever. Each harvest and every batch of extract carries the potential to bring a company closer to trust or disaster. Trust, in this context, is multi-layered, encompassing regulators, investors, retail partners, and consumers. One lapse in quality or consistency can erode all these relationships, making the journey back to credibility both costly and time-consuming. The difference often comes down to standards compliance. “My previous experiences in lab equipment and appliances allowed me to understand cannabis manufacturing is a cross between consumer packaged goods (CPG) and pharmaceuticals,” said Xylem Robotics founder Jeff Wu. “And central to the success of CPG and pharmaceuticals is a well-run supply chain with product consistency and quality. We actually screen our potential clients to see if they understand basic supply chain principles, because we want the people who purchase Xylem products to be successful in this market.” The screening process is about more than technical knowledge. The Xylem team also attempts to ensure operators understand how product flow, traceability, and documentation affect the bottom line. Wu emphasized foundational operational understanding is a prerequisite to responsible scaling. For decades, cannabis operated outside traditional regulatory frameworks that come naturally to the much more mature CPG and pharmaceutical industries. But as legalization expands, regulators and consumers alike expect the industry to play by the same rules as other industries. That means documenting everything, ensuring traceability, managing risk and, above all, maintaining a culture that mandates quality. Building this culture is not a matter of simply posting rules on a wall; it requires hands-on leadership, consistent training, and clear communication so every employee understands their role in maintaining compliance and product safety. Preparing for Increased Federal Oversight Few people understand both the urgency and the opportunity better than Wu. After years of building systems that helped companies in highly regulated markets avoid recalls and survive audits, he entered cannabis with a pragmatic message: Good Manufacturing Practices (GMP) aren’t optional. They’re inevitable. Those who prepare now will not only survive federal scrutiny but also thrive in a more mature, trusted marketplace. Preparation involves assessing existing workflows, identifying gaps in training or documentation, and making capital investments strategically, rather than reactively, to support long-term growth. That’s easier said than done. Many operators are trying to scale production in a patchwork of state-by-state regulations while managing thin margins, talent shortages, and constant competitive pressure. The combination of rapid growth expectations and limited operational experience creates stress points that often manifest in inconsistent product quality, delayed shipments, or compliance oversights, all of which can jeopardize contracts and investor confidence. Operators who embrace standardized practices put forth by GMP and the International Organization for Standardization (ISO) now will be ready for a federally regulated market in the future. Those who don’t will be exposed to operational, legal, and financial risk that scales with their production volume. Wu broke down the current state of cannabis manufacturing, the inevitability of federal regulation, and why building a strong culture of standards compliance today will determine who leads tomorrow. His insights emphasize operational excellence is both a defensive and offensive strategy that prevents failures while positioning companies to win in a competitive, evolving market. [image: Jeff Wu pullquote graphic] The State of Manufacturing Compliance At first glance, cannabis manufacturing resembles any other CPG operation: Inputs enter the system, and products come out. But under the surface, a fundamental question defines the success of the entire process: batch or flow? “Think of home brewers versus a beer factory,” Wu said. “Batch manufacturing [as in home brewing] groups products into lots, with the entire batch moving through each production stage sequentially. This offers flexibility but ultimately can lead to downtime and higher total manufacturing time and cost.” One potential issue with batch manufacturing, he pointed out, may occur when a manufacturing defect is discovered during the production cycle. In that case, the entire batch must be disposed of or processed again. In contrast, flow manufacturing pushes products through the system one at a time, from start to finish without interruption. This creates a steady stream of output, reducing lead times and increasing consistency while lowering per-unit costs. However, flow systems generally require a larger investment up front. “Regulations drive up the cost of compliance or product standards,” Wu said. “Flow manufacturing solves these issues head-on with consistency and quality, which are key drivers of success for consumer products. “Early on, when I was an investor-operator in a California cannabis manufacturing facility, the first proto-Xylem cartridge-filling system we built was a flow manufacturing system to compete with much larger competitors like Select. It was our secret weapon, so to speak.” For context, most cannabis companies operate with a batch system. Flower is harvested, processed, and packaged in lots. It’s then measured by the pound, the run, or the day. This approach fits the plant’s agricultural roots but leaves gaps in traceability and risk management. In contrast, flow systems, which are common in food and pharmaceuticals, continuously track inputs and outputs. This creates a tighter, more transparent chain of custody. Wu explained why flow systems are essential for scaling. “If you batch 200 units, you’ll be profitable,” he said. “Batch 400, still okay. But at 1,000, cracks start to form. By 10,000, you’re losing money and exposing your company to operational risk. One misstep at a million [production] units can be catastrophic. Even paint specks or minor contamination can trigger multimillion-dollar legal exposure.” He added labor costs in the United States make batch systems fundamentally unscalable at high volumes. “Comparing batch and flow, one is efficient and one is not,” he said. “One is scalable; one is not. All large-scale manufacturing requires flow-based systems. Even pharmaceuticals are flow-based. If people think they can scale a batch approach, they’re in for a big shock.” Lessons from Other Industries Wu encourages operators across the spectrum to take lessons from other tightly regulated sectors that are well-established. “If you’re working in meat packaging or foods, there is zero possibility you’re not going to hurt someone if you don’t adhere to GMP and ISO standards,” he said. “In cannabis, things like gummies are at least a little safer. Once you get water out, sugar is a natural preservative. But, I’d still be worried about mold, especially in flower. And when it comes to drinks, I’m worried about potential bacterial issues.” He emphasized cannabis is not a hype-driven product like energy drinks. Products require disciplined manufacturing practices and reliable supply chains. Compliance is more than merely a legal checkbox. It’s a financial safeguard, Wu said. Recalls, fines, and lawsuits are not theoretical risks; they can be operational landmines. “GMP and ISO standards ensure products are produced safely, consistently, and with quality,” he explained. “When federal legalization occurs, these standards will most likely be mandated and compulsory, but this is not what most operators want to hear due to the equipment and capital investments needed to comply. However, if operators take a pragmatic approach, GMP and ISO standards mean product consistency and quality. These lead to customer satisfaction and, more importantly, customer retention. GMP and ISO standards control for equipment and processes hygiene, which builds in risk management, and that minimizes costly recalls and legal exposure.” The potential for federal regulation already is causing shifts in the market. Investors are starting to ask tougher questions about compliance readiness, Wu said. Retail buyers want assurances products are manufactured to the same standards used in traditional consumables sectors. In addition, employees are more willing to work for companies that value safety and consistency. For operators wondering how to prepare for GMP and ISO standards, Wu offered a simple recommendation: Begin with documentation. Creating standard operating procedures (SOPs) and logging processes can pay immediate dividends even for businesses that are not ready for full GMP certification. Establishing written SOPs trains teams to think systematically and creates a paper trail that regulators and investors can trust. “I came into the cannabis market during the 2018 California legalization frenzy with investments into Eaze and a processing facility,” he revealed. “The people who brought me into this market were the ‘tech bro’ crowd who were interested in fast money and fast exits. Most had little interest in understanding supply chains or manufacturing and even less interest in running such a company. “But at the end of the day, hundreds of millions of dollars of investment capital cannot change the fact that cannabis is a perishable product that needs to be physically manufactured and requires strict supply chain management to generate profits,” he continued. “Success means simple, fundamentally sound business models with durable competitive advantages centered around product consistency and quality versus complex, flashy trends.” The industry may still be years away from federal legalization, but for manufacturers, the clock is ticking. Standards compliance is not a one-time project; it’s an ongoing discipline. The companies that take it seriously today will be the ones that remain standing tomorrow. “What’s fun about watching people with [Xylem’s] systems is, a lot of operators are running the model we wanted to run back when we were operators,” Wu said, chuckling. “Now you see operators actually using these systems the way they’re designed to be used.” Many new operators enter the industry with a fundamental misunderstanding about the nature of the business, underestimating the harsh realities of manufacturing in a highly regulated space, he said. Today’s industry may not be subject to FDA oversight, but that day is coming. Developing the discipline required to consistently produce a product at scale is crucial, he said—and the sooner operators embrace that truth, the better for their bottom lines. “Cannabis is a manufacturing business with hard costs of goods, and you will never get around that fact,” Wu said. “If you think this will be two to three years and then you can go sit on a beach, that’s not going to happen. Be ready to run a proper company that does true manufacturing work. Success comes from doing it well and producing products people want to buy.” For operators, adopting GMP and ISO standards now will deliver more than a competitive advantage. Upgrading operations will prepare businesses for an industry that most likely will be increasingly regulated, scrutinized, and operationally demanding. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

A citizen initiative in Maine, backed by GOP operatives, seeks to repeal the state's commercial adult-use marijuana market and strip consumers of the right to grow their own plants, nearly 10 years after voters legalized recreational cannabis. The proposal would keep possession of up to 2.5 ounces legal for adults and leave the medical cannabis program intact. Proponents need approval from the secretary of state's office before circulating petitions. Opponents, like Rep. David Boyer (R), are concerned the effort ignores the will of Maine voters and would empower the black market. < Back New Maine Ballot Initiative Would Roll Back Marijuana Legalization Law Approved By Voters Oct 30, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link There’s another effort brewing to undermine a state voter-approved marijuana law—this time in Maine, where a citizen initiative backed by GOP operatives has been submitted in hopes of rolling back the commercial adult-use market. Almost 10 years after Maine voters passed a recreational legalization measure at the ballot, a group of voters—including a Republican state senator and a former top staffer to then-Gov. Paul LePage (R), a staunch prohibitionist—filed a petition to repeal much of the law with the secretary of state’s office last month. This comes as a separate campaign in Massachusetts says it’s “on track” to turn in enough signatures to qualify their own initiative to roll back cannabis legalization for the state’s 2026 ballot. In Maine, the citizen initiative application led by Madison Carey and signed by state Sen. Scott Cyrway (R), former LePage senior policy advisor Nicholas Adolphsen and others describes a broad repeal of current statutes allowing for the retail sale of cannabis to adults, while also stripping consumers of the right to grow their own plants for personal use. Possession of up to 2.5 ounces of marijuana by adults would remain legal under the proposal. And the state’s medical cannabis program would remain intact. The draft initiative must be approved by the secretary of state’s office before proponents can circulate petitions, and a spokesperson for that office told Marijuana Moment on Wednesday that the petitioners have since “asked for changes to the proposed bill from the Revisor’s office.” “Once that is back, it will need to go to another office for a fiscal impact statement, and only then can the Elections staff layout and issue the petition,” they said. Carey, the chief petitioner, did not immediately respond to a request for comment from Marijuana Moment. So it remains unclear what, if any, substantive changes they’re asking the state to make to the ballot language. As currently drafted, however, the initiative also details a process by which the Office of Cannabis Policy would need to streamline requests from existing adult-use businesses to convert to medical marijuana licensees. It would also allow cannabis products available in recreational shops to be sold or transferred to medical marijuana licensees. Rep. David Boyer (R), who led the fight to pass the cannabis legalization initiative on Maine’s ballot in 2016 when he was a staffer for the Marijuana Policy Project, said told Marijuana Moment he is “deeply concerned” by the new prohibitionist campaign. “This effort ignores the will of Maine voters who chose to end the failed era of prohibition nearly a decade ago,” he said. “Since legalization, Maine has generated hundreds of millions in tax revenue; created thousands of good-paying Maine jobs; and replaced a dangerous black market with a safe, regulated system that prioritizes consumer safety and quality control.” “We’ve avoided the pitfalls seen in other states by fostering a market that supports small businesses and local growers,” Boyer said. “Turning back now would only empower criminal enterprises, waste taxpayer dollars on ineffective enforcement, and infringe on the personal freedoms of responsible adults.” Outside of the ballot process, there have been multiple recent attempts to undermine state marijuana laws in legislatures across the country, generating criticism for advocates who have blasted primarily GOP lawmakers for going against the interests of the majority who favor reform. *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* Back in Maine, legislators in June reversed course and rejected a bill to legalize possession of up to one ounce of psilocybin by adults 21 and older. That followed a separate effort in the state last year to legalize psilocybin and allow adults to access the psychedelic at state-licensed facilities. But lawmakers watered down that bill—amending it to create a commission to further explore the reform instead—and it ultimately did not pass. Meanwhile, Maine lawmakers in February voted to investigate possible conflicts of interest by a top marijuana official. And last year, a law took effect allowing people to apply to have records of now-legal marijuana crimes sealed. *Read the text of the draft ballot initiative to repeal Maine’s commercial marijuana market below:* The post New Maine Ballot Initiative Would Roll Back Marijuana Legalization Law Approved By Voters appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

As the cannabis industry matures, access to reliable data is more important than ever. Where to find cannabis industry data online is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Back Where to find cannabis industry data online May 28, 2025 Andrew Long MJ Biz Daily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link As the cannabis industry matures, access to reliable data is more important than ever. Where to find cannabis industry data online is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Sesh by Sherlocks started as a glass museum and has grown to become North Carolina's leading brand for THCA flower and live rosin. < Back Meet Sesh by Sherlocks Glass—North Carolina’s leading THCA flower and live rosin brand, born from a glass museum Dec 23, 2025 Leafly Staff Leafly Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Sesh by Sherlocks has grown to North Carolina's top destination for THCA flower after beginning as a glass museum. The post Meet Sesh by Sherlocks Glass—North Carolina’s leading THCA flower and live rosin brand, born from a glass museum appeared first on Leafly. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Marijuana multistate operator Curaleaf Holdings sued New Jersey regulators on October 9th to avoid punishment for violating a union rule, a post from MJBizDaily reports. < Back Marijuana MSO Curaleaf sues New Jersey to avoid ‘death penalty’ Oct 22, 2025 Chris Roberts MJbizDaily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Marijuana multistate operator Curaleaf Holdings sued New Jersey regulators on Oct. 9 to avoid serious punishment for violating a union rule. Marijuana MSO Curaleaf sues New Jersey to avoid ‘death penalty’ is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5